Scholarlink

Background <p>Methotrexate (MTX) toxicity is a life-threatening complication in oncology patients.</p> Case presentation <p>We report a 19-year-old male with newly diagnosed Burkitt lymphoma who received high-dose methotrexate as part of induction chemotherapy and initially met protocol-defined serum clearance criteria with suspected delayed MTX toxicity. This prolonged toxicity was due to possible redistribution from extravascular fluid compartments in the setting of severe fluid overload and renal dysfunction. Five weeks after methotrexate administration, a detectable serum methotrexate concentration (0.4&#xa0;µmol/L) was identified despite no additional exposure. His course was complicated by tumor lysis syndrome, pleural effusions and anasarca, bowel perforations requiring multiple surgeries, acute respiratory distress syndrome, persistent pancytopenia, progressive renal and hepatic dysfunction, recurrent infections, and multiorgan failure. Despite treatment with leucovorin, urine alkalinization, continuous kidney replacement therapy, and high-flux hemodialysis, serum MTX concentrations demonstrated recurrent detectable elevations.</p> Conclusions <p>This case highlights how altered pharmacokinetics in critical illness may render serum clearance thresholds unreliable and underscores the need for heightened clinical suspicion for delayed drug toxicity in critically ill patients with dynamic volume shifts or unexplained multiorgan dysfunction.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Delayed methotrexate toxicity after initial clearance in a critically ill patient with severe fluid overload

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月31日

查看全文
  • April Slamowitz,
  • Rachel Kessel,
  • Liron M. Fedida,
  • Reid LaPlante,
  • Adam Beaton

摘要

Background

Methotrexate (MTX) toxicity is a life-threatening complication in oncology patients.

Case presentation

We report a 19-year-old male with newly diagnosed Burkitt lymphoma who received high-dose methotrexate as part of induction chemotherapy and initially met protocol-defined serum clearance criteria with suspected delayed MTX toxicity. This prolonged toxicity was due to possible redistribution from extravascular fluid compartments in the setting of severe fluid overload and renal dysfunction. Five weeks after methotrexate administration, a detectable serum methotrexate concentration (0.4 µmol/L) was identified despite no additional exposure. His course was complicated by tumor lysis syndrome, pleural effusions and anasarca, bowel perforations requiring multiple surgeries, acute respiratory distress syndrome, persistent pancytopenia, progressive renal and hepatic dysfunction, recurrent infections, and multiorgan failure. Despite treatment with leucovorin, urine alkalinization, continuous kidney replacement therapy, and high-flux hemodialysis, serum MTX concentrations demonstrated recurrent detectable elevations.

Conclusions

This case highlights how altered pharmacokinetics in critical illness may render serum clearance thresholds unreliable and underscores the need for heightened clinical suspicion for delayed drug toxicity in critically ill patients with dynamic volume shifts or unexplained multiorgan dysfunction.